Why we prefer levetiracetam over phenytoin for treatment of status epilepticus. (6th April 2018)

• Record Type: Journal Article
• Authors: Zaccara, G.; Giorgi, F. S.; Amantini, A.; Giannasi, G.; Campostrini, R.; Giovannelli, F.; Paganini, M.; Nazerian, P.
• Is Part Of: Acta neurologica Scandinavica. Volume 137:Number 6(2018)
• Page Start: 618
• Page End: 622
• Publication Date: 2018-04-06
• Subjects: antiepileptic drugs -- convulsive status epilepticus -- focal status epilepticus -- lacosamide -- fosphenytoin -- valproate; Neurology -- Periodicals; 616.8
• DOI: 10.1111/ane.12928
• Languages: English
• ISSNs: 0001-6314

Abstract

Abstract : Over last fifty years, intravenous (iv) phenytoin (PHT) loading dose has been the treatment of choice for patients with benzodiazepine‐resistant convulsive status epilepticus and several guidelines recommended this treatment regimen with simultaneous iv diazepam. Clinical studies have never shown a better efficacy of PHT over other antiepileptic drugs. In addition, iv PHT loading dose is a complex and time‐consuming procedure which may expose patients to several risks, such as local cutaneous reactions (purple glove syndrome), severe hypotension and cardiac arrhythmias up to ventricular fibrillation and death, and increased risk of severe allergic reactions. A further disadvantage of PHT is that it is a strong enzymatic inducer and it may make ineffective several drugs that need to be used simultaneously with antiepileptic treatment. In patients with a benzodiazepine‐resistant status epilepticus, we suggest iv administration of levetiracetam as soon as possible. If levetiracetam would be ineffective, a further antiepileptic drug among those currently available for iv use (valproate, lacosamide, or phenytoin) can be added before starting third line treatment.